SE9900473D0 - Inhibitor of endothelial cell proliferation - Google Patents

Inhibitor of endothelial cell proliferation

Info

Publication number
SE9900473D0
SE9900473D0 SE9900473A SE9900473A SE9900473D0 SE 9900473 D0 SE9900473 D0 SE 9900473D0 SE 9900473 A SE9900473 A SE 9900473A SE 9900473 A SE9900473 A SE 9900473A SE 9900473 D0 SE9900473 D0 SE 9900473D0
Authority
SE
Sweden
Prior art keywords
angiogenesis
egcg
inhibitor
cell proliferation
endothelial cell
Prior art date
Application number
SE9900473A
Other languages
English (en)
Inventor
Cao Yihai
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE9900473A priority Critical patent/SE9900473D0/sv
Publication of SE9900473D0 publication Critical patent/SE9900473D0/sv
Priority to PCT/IB2000/000193 priority patent/WO2000047193A2/en
Priority to AU25673/00A priority patent/AU2567300A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9900473A 1999-02-12 1999-02-12 Inhibitor of endothelial cell proliferation SE9900473D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9900473A SE9900473D0 (sv) 1999-02-12 1999-02-12 Inhibitor of endothelial cell proliferation
PCT/IB2000/000193 WO2000047193A2 (en) 1999-02-12 2000-02-14 Inhibition of angiogenesis with epigallocatechin-3-gallate
AU25673/00A AU2567300A (en) 1999-02-12 2000-02-14 Inhibition of angiogenesis with epigallocatechin-3-gallate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900473A SE9900473D0 (sv) 1999-02-12 1999-02-12 Inhibitor of endothelial cell proliferation

Publications (1)

Publication Number Publication Date
SE9900473D0 true SE9900473D0 (sv) 1999-02-12

Family

ID=20414446

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900473A SE9900473D0 (sv) 1999-02-12 1999-02-12 Inhibitor of endothelial cell proliferation

Country Status (3)

Country Link
AU (1) AU2567300A (sv)
SE (1) SE9900473D0 (sv)
WO (1) WO2000047193A2 (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074662A2 (en) * 1999-06-07 2000-12-14 University Of Sheffield Arthritis treatment
US6248341B1 (en) * 2000-01-14 2001-06-19 Color Access, Inc. Method of treating topical angiogenesis-related disorders
WO2002064178A1 (en) * 2001-02-15 2002-08-22 William Ransom & Son Plc Use of green tea extract for wound healing
GB0103742D0 (en) * 2001-02-15 2001-04-04 William Ransom & Son Plc Wound healing
CA2471750A1 (en) 2001-12-28 2003-07-17 Research Development Foundation Polyphenol inhibition of nucleoside diphosphate kinase-b activity and cancer metastasis
FR2842102B1 (fr) * 2002-07-10 2005-10-28 Cep Utilisation d'un extrait de the pour controler la liberation d'il8, cytokine pro-inflammatoire et son incorporation dans des preparations cosmetiques et/ou dermatologiques
PT102931B (pt) * 2003-03-28 2005-08-31 Univ Do Porto Utilizacao de bloqueadores da inibicao a longo termo das actividades da atpase na+k+e/ou do trocador na+/h+, na preparacao de um medicamento destinado a terapiaintestinal
WO2005000330A1 (en) 2003-05-28 2005-01-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Angiogenic agents from plant extracts, gallic acid, and derivatives
KR100601080B1 (ko) 2004-08-26 2006-07-19 가톨릭대학교 산학협력단 (-)-에피갈로카테킨 갈레이트를 유효성분으로 하는류마티스성 관절염 치료제
US20070249545A1 (en) * 2004-08-27 2007-10-25 Rodriguez-Lopez Jose N Dihydrofolate reductase inhibition by epigallocatechin gallate compounds
EP1704862A1 (en) * 2005-03-24 2006-09-27 Rottapharm S.p.A. 2,5-bis(tetrahydroxybutyl)pyrazines for the treatment of osteoarthritis and rheumatoid arthritis
DE102005029845B4 (de) 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Verfahren zur Diagnose von rheumatischen Erkrankungen
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US20090226547A1 (en) * 2008-03-05 2009-09-10 Gilbard Jeffrey P Dietary Supplement For Eye Health
TW201412325A (zh) 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療
CN108272794A (zh) * 2018-01-17 2018-07-13 苏州大学 表没食子儿茶素没食子酸酯的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238728A (ja) * 1985-04-16 1986-10-24 Mitsui Norin Kk 茶葉抽出物と活性水酸化アルミニウムとの抗潰瘍性複合体
JP2903318B2 (ja) * 1989-04-04 1999-06-07 日研フード株式会社 抗酸化的ストレス物
JP3002919B2 (ja) * 1991-11-25 2000-01-24 太陽化学株式会社 胃炎，胃または十二指腸潰瘍防止組成物
JPH08217674A (ja) * 1995-02-16 1996-08-27 Noda Sangyo Kagaku Kenkyusho ヒスチジン脱炭酸酵素阻害剤
IT1275905B1 (it) * 1995-03-14 1997-10-24 Indena Spa Frazioni polifenoliche di te', loro uso e formulazioni che le contengono
CA2175985A1 (en) * 1995-05-10 1996-11-11 Yoichi Kiyosuke Pharmaceutical composition containing substance inhibiting hsp47 production
JPH09227374A (ja) * 1996-02-28 1997-09-02 Taiyo Kagaku Co Ltd ストレスタンパク質産生抑制組成物
DE19627344A1 (de) * 1996-07-01 1998-01-08 Vitasyn Gmbh Entwicklung & Ver Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenolverbindungen
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
JP4507027B2 (ja) * 1998-12-04 2010-07-21 明治乳業株式会社 Ｍｍｐ阻害剤

Also Published As

Publication number Publication date
WO2000047193A3 (en) 2001-12-06
WO2000047193A2 (en) 2000-08-17
AU2567300A (en) 2000-08-29

Similar Documents

Publication Publication Date Title
SE9900473D0 (sv) Inhibitor of endothelial cell proliferation
Badimon Atherosclerosis and thrombosis: lessons from animal models
ATE352303T1 (de) Pharmazeutisch wirksame isoindolinderivate
Martinelli et al. The transition G to A at position 20210 in the 3′-untranslated region of the prothrombin gene is not associated with cerebral ischemia
Lohsiriwat et al. Comparison of the ionic silver-containing Hydrofiber* and paraffin gauze dressing on split-thickness skin graft donor sites
Maitre et al. Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine
Gustafsson et al. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time
Qian et al. Overexpression of PAI-1 prevents the development of abdominal aortic aneurysm in mice
Hess Arterial ulcer checklist
RU2003124748A (ru) Фармацевтические композиции, которые подавляют сосудистую пролиферацию, и способ их применения
Leite et al. Dimethyl sulfoxide as a block to the deleterious effect of nicotine in a random skin flap in the rat
Zimmerman et al. Surgical implications of therapeutic angiogenesis
Ray et al. Epsilon-aminocaproic acid promotes the release of α2-antiplasmin during and after cardiopulmonary bypass
Fleck et al. Newer debridement methods for wound bed preparation
Fingleton et al. Matrix metalloproteinases as targets for therapy in Kaposi sarcoma
Luttun et al. Genetic studies on the role of proteinases and growth factors in atherosclerosis and aneurysm formation
Cole et al. Adjuvant use of acoustic pressure wound therapy for treatment of chronic wounds: a retrospective analysis
Singh et al. Tangential excision and skin grafting for ash burns of the foot in children: a preliminary report
Gweon et al. Treatment of cyclophosphamide induced hemorrhagic cystitis with neodymium: YAG laser in pediatric patients
Mulrow et al. Guiding lights for antihypertensive treatment in patients with nondiabetic chronic renal disease: Proteinuria and blood pressure levels?
Price Jr New pieces for the puzzle: nonsteroidal anti-inflammatory drugs and corneal ulcers
Bredbacka et al. Disseminated intravascular coagulation in neurosurgical patients: diagnosis by new laboratory methods
Keramidas et al. Adult hand injuries on artificial ski slopes
DE69928539D1 (de) Zielrichtung und verlängerte assoziation von wirkstoffen an die luminale oberfläche der pulmonaren vaskularen endothelzellen
van Diest et al. Vital exhaustion: Behavioural and biological correlates